Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.500.36%
QQQ
708.060.06%
BTC/USD
77368.920.0305%
DIA
529.490.33%
GLD
400.711%
TLT
81.880.01%

Monopar Therapeutics Inc

MNPRNASDAQ
Trade with Public
Trade with Public
$116.20
-1.37-1.17%
Last update: Sep 2, 1:35 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Monopar Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Monopar Therapeutics (MNPR).

Price Target Range — 10 Quarters

Analyst Consensus — 14 Analysts

12Buy
2Hold
Consensus RatingBuy# Analysts14Avg. Consensus PT$96Upside to Avg. PT-17.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026BarclaysEtzer DaroutPT RaiseOverweight$125→$128
Aug 13, 2026Cantor FitzgeraldKristen KluskaDowngradeOverweight→Neutral$109→$119
More with Benzinga EdgeGet Access

Analyst Ratings News

This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.
Avi Kapoor

PRO
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128

Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119

Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved